Incidence of and Risk Factors for Paradoxical Psoriasis or Psoriasiform Lesions in Inflammatory Bowel Disease Patients Receiving Anti-TNF Therapy: Systematic Review With Meta-Analysis

Wenhui Xie†, Shiyu Xiao‡, Hong Huang† and Zhuoli Zhang*†

†Department of Rheumatology and Clinical Immunology, Peking University First Hospital, Beijing, China, ‡Department of Gastroenterology, Peking University Third Hospital, Beijing, China

Background: Paradoxical psoriasis or psoriasiform lesions induced by anti-tumor necrosis factor (anti-TNF) therapies receive increasing attention worldwide. However, no comprehensive meta-analysis investigating the incidence estimates and risk factors for anti-TNF-induced psoriasis is currently available. We aimed to precisely quantify its incidence as well as risk factors in patients with inflammatory bowel disease (IBD).

Methods: This study was registered on PROSPERO database under review registration number CRD42021233695. The electronic databases PubMed, EMBASE, and the Cochrane library were comprehensively searched for observational studies published as full-length papers in English and reporting the incidence and/or predictors for psoriasis or psoriasiform lesions in IBD patients. A random-effects meta-analysis was performed to calculate the pooled incidence. Pooled odds ratio (OR) and 95% confidence interval for potential predictors were combined using a fixed-effects or random-effects model.

Results: In total, 30 articles comprising 24,547 IBD patients treated by anti-TNF were finally included. The overall pooled incidence of psoriasis and/or psoriasiform lesions following anti-TNF therapy was 6.0% (5.0–7.0%; I² = 93.9%), with 6.9% (5.1–8.7%; I² = 92.4%) for psoriasiform lesions and 4.6% (3.6–5.6%; I² = 93.9%) for psoriasis. Multivariable meta-regression analysis indicated regions and populations that significantly contributed to the heterogeneity. A statistically higher risk for psoriasis or psoriasiform lesions during anti-TNF therapy was observed in female patients (OR 1.46, 1.23–1.73), those who are at a younger age at anti-TNF initiation (OR 1.03, 1.00–1.05), smokers (OR 1.97, 1.56–2.48), ileocolonic Crohn’s disease patients (OR 1.48, 1.03–2.13), and those who are using adalimumab or certolizumab (vs. infliximab) (OR: 1.48 and 2.87 respectively).
Conclusions: The incidence of psoriasis or psoriasiform lesions was not uncommon in IBD patients following anti-TNF therapy. Female, younger age, smoker, ileocolonic Crohn’s disease, and the types of anti-TNF were significantly associated with such risk. These findings may help gastroenterologists to make more individualized decisions and understand the mechanisms of this paradoxical phenomenon.

Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=233695, identifier CRD42021233695.

Keywords: inflammatory bowel disease, anti-tumor necrosis factor, psoriasis, psoriasiform lesions, risk factors, meta-analysis, incidence

INTRODUCTION

Inflammatory bowel diseases (IBDs) are chronic inflammatory disorders of the gastrointestinal tract that affect approximately 10 million patients worldwide (1, 2). The introduction of biologics has dramatically transformed the therapeutic landscape of IBD. Among these, anti-tumor necrosis factor (anti-TNF), such as infliximab and adalimumab, are most extensively used in daily practice for a couple of decades (3). Accumulative evidence has demonstrated that anti-TNF can control the disease activity rapidly, exert a steroid-sparing effect, promote mucosal healing, improve the quality of life, and reduce the risk of surgery as well (3, 4).

With increasing use of these agents, however, some paradoxical inflammations, involving the skin, joints and lungs, have been described and received increasing attention in recent years (5). Of these, paradoxical psoriasis or psoriasiform lesion induced by anti-TNF therapies is one of the most extended concerned topics worldwide. Generally, anti-TNF treatments are commonly used for psoriasis therapy, but psoriasis and psoriasiform skin lesions are sometimes observed in IBD patients receiving anti-TNF therapies. Overall, IBD patients treated with anti-TNF therapy have a 2.4-fold increased risk of paradoxical psoriasis compared with nonusers of anti-TNF (6). Meanwhile, there is high inconsistency in the results of previous studies on the incidence of psoriasis or psoriasiform lesions in IBD patients with exposure to anti-TNF, varying from 1% (6) to more than 30% (7). The relatively small sample sizes and limited number of events lead to significant variation and imprecise incidence estimates and further preclude robust conclusions to be drawn from any of the individual studies. On the other hand, currently, the knowledge about the risk factor for psoriasis or psoriasiform lesions secondary to anti-TNF therapy in IBD patients is limited and contradictory—for example, some
studies have shown gender, smoking, and concomitant immunosuppressive agents to be associated with an increased risk of developing anti-TNF-induced psoriasis, while others have not (8–16).

To date, no comprehensive meta-analysis investigating the incidence estimates and risk factors for anti-TNF-induced psoriasis is currently available. To fill the gap, the present study is intended to precisely quantify the incidence of and risk factors for developing anti-TNF-induced psoriasis or psoriasiform lesions in IBD patients.

MATERIALS AND METHODS

This article was carried out and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analysis (17). The methods were stipulated in a protocol that was registered with PROSPERO (CRD42021233695).

Literature Search and Inclusion Criteria

A literature search of English language publications was performed using the electronic databases PubMed, EMBASE, and the Cochrane Library from database inception to February 9, 2021. The search strategy was designed and conducted by an experienced medical librarian with input from the study investigators. The studies were identified by combining three search themes: the first theme, inflammatory bowel disease; the second theme, anti-TNF; and the third theme, a combination of the following terms: psoriasis, psoriasiform, dermatological, skin, and cutaneous. The detailed search strategies are available in Supplementary Appendix S1.

Studies were included if they were on IBD patients of all ages (including children) receiving anti-TNF treatment, were cohort studies or case–control studies, reported the incidence of and/or risk factors for psoriasis or psoriasiform lesions in IBD patients, and were full-text English articles. When duplicate publications were identified, only the article with the newest and most comprehensive information was included. We excluded studies with insufficient data of interest (such as those only presenting all dermatological events), meeting abstract, case report, editorial, review, or nonhuman investigations. Two investigators (WX and SX) independently evaluated the eligibility, and any discrepancy throughout was resolved by a third investigator (ZZ).

Data Extraction and Outcome Assessment

Data extraction of the eligible studies was conducted by two independent review authors (WX and SX) using piloted data extraction sheets: first author, publication year, country/countries, study design, data sources, setting, study period, the diagnosis of IBD, psoriasis, sample size, time period of observations, patients’ demographics and clinical characteristics, number of patients developing psoriasis or psoriasiform lesions, risk factor of interests, and risk estimates. The methodological quality of each study was rated by the Newcastle–Ottawa Scale (NOS) which consists of three factors: patient selection (0–4 points), comparability of the study groups (0–2 points), and assessment of outcome (0–3 points) (18). All relevant studies were scored from 0 to 9 on the NOS to determine the study quality.

Data Synthesis and Analysis

All calculations and graphs were performed using Stata Statistical Software version 13.0. The incidence of psoriasis or psoriasiform lesions in IBD patients treated with anti-TNF therapy was pooled. The levels of heterogeneity were assessed by the I² statistic ($I^2 >50\%$ was considered as a statistically significant heterogeneity). If severe heterogeneity was present at $I^2 >50\%$, the random-effects model (DerSimonian and Laird method) was chosen; otherwise, the fixed-effects model was adopted (Mantel–Haenszel method). The sources of heterogeneity were explored by using subgroup and meta-regression analyses. On the other hand, to explore the risk factors for developing psoriasis or psoriasiform lesions, the patients’ demographics and clinical characteristics (sex, age, smoking, disease phenotype, type of anti-TNF therapy, etc.) were compared between IBD patients with and without psoriasis/psoriasiform lesions during anti-TNF therapy, if possible. Pooled odds ratios (ORs) with 95% CI were calculated as an effect measure. We extracted the risk estimates that were adjusted for most variables. When no raw data were available, relative risks and hazard ratios were taken as good estimates of OR, in line with previous reports (19–21). Sensitivity analyses were performed to assess the robustness of estimates. Graphical symmetry with funnel plot, as well as with Begg’s and Egger’s statistical tests, was produced to help detect publication bias. Trim-and-filled method was performed in the case of potential publication bias. A two-sided P-value <0.05 was considered statistically significant.

RESULTS

Study Selection and Characteristics

The study selection process is shown in Supplementary Figure S1. Initially, we retrieved 11,467 citations, of which 107 full-text articles were eligible for inclusion (6–16, 22–40). The characteristics of the included studies are presented in Table 1. In total, 30 citations were published between 2009 and 2020. All papers were based on retrospective or prospective cohorts, and majority of them originated from Europe and the USA. Psoriasis or psoriasiform lesions diagnosis was mostly judged by the treating gastroenterologist and/or dermatologist (biopsy if necessary) (8, 10, 13–16, 22, 26, 29–31, 33–37). The median NOS score in the included studies was 6, ranging from 5 to 8 (Supplementary Table S1).

The Incidence of Psoriasis or Psoriasiform Lesions

The incidence of psoriasis or psoriasiform lesions associated with anti-TNF therapy in IBD patients was reported by 29 articles, varying from 1.1 to 29.8%. In total, 913 cases were documented from 24,547 patients with IBD exposed to anti-TNF agents, corresponding to a crude incidence of 3.7%. The overall pooled incidence of psoriasis and/or psoriasiform lesions following anti-
TABLE 1 | Characteristics of the studies included in the meta-analysis.

| Author, Reference | Year | Country | Data source | Study design | Enrollment period | Population | Number of IBD | Outcome | Diagnosis method | Number of events |
|-------------------|------|---------|-------------|--------------|------------------|------------|--------------|---------|-----------------|-----------------|
| Fidder et al. (22) | 2009 | Belgium | Monocenter | Retrospective | 1994–2008 | Adult | 743 | Psoriasisform lesions | Patient or treating physician | 39 |
| Rahier et al. (23) | 2010 | France | Multicenter | Retrospective | 2004–2009 | Adult | 562 | Psoriasisform lesions | NA | 62 |
| Baumgart et al. (24) | 2011 | Germany | Monocenter | Prospective | NA | Mixed | 50 | Psoriasisform lesions | NA | 6 |
| Hiremath et al. (25) | 2011 | USA | Monocenter | Retrospective | NA | Children | 73 | Psoriasis | Gastroenterologists and dermatologists; biopsy if necessary | 6 |
| Guerra et al. (26) | 2012 | Spain | Multicenter | Retrospective | NA | Mixed | 1,294 | Psoriasis |NA | 21 |
| Salgueiro et al. (27) | 2013 | Portugal | Monocenter | Retrospective | 2002–2012 | NA | 132 | Psoriasis | NA | 11 |
| Sherlock et al. (28) | 2013 | Canada | Monocenter | Retrospective | 2000–2010 | Children | 172 | Psoriasisform lesions | NA | 18 |
| Afzali et al. (29) | 2014 | USA | Monocenter | Retrospective | 1998–2011 | Mixed | 1,004 | Psoriasisform lesions | Gastroenterologists | 27 |
| Malkönen et al. (7) | 2014 | Finland | Monocenter | Prospective | 2011–2013 | Children | 84 | Psoriasisform lesions | NA | 25 |
| Tiltack et al. (30) | 2014 | Germany | Monocenter | Prospective | 2010–2011 | Adult | 434 | Psoriasisform lesions | Dermatologists | 21 |
| Włodarczyk et al. (31) | 2014 | Poland | Monocenter | Prospective | 2012–2013 | Adult | 30 | Psoriasisform lesions | Gastroenterologists and dermatologists | 8 |
| Pugliese et al. (32) | 2015 | Italy | Monocenter | Retrospective | 2008–2013 | Adult | 402 | Psoriasis | Dermatologists | 42 |
| Fréling et al. (33) | 2015 | France | Monocenter | Retrospective | 2000–2011 | Adult | 583 | Psoriasisform lesions | Dermatologists | 59 |
| George et al. (34) | 2015 | USA | Monocenter | Retrospective | 2004–2013 | Mixed | 72 | Psoriasisform lesions | Dermatologists | 18 |
| Huang et al. (35) | 2015 | Canada | Monocenter | Retrospective | 2013 | Adult | 71 | Psoriasis | Gastroenterologists and dermatologist | 2 |
| Soh et al. (36) | 2015 | Republic of Korea | Monocenter | Retrospective | 2002–2013 | NA | 500 | Psoriasisform lesions | Dermatologist | 13 |
| Cleynen et al. (37) | 2016 | Belgium | Monocenter | Retrospective | 1994–2009 | Adult | 917 | Psoriasisform lesions, psoriasis | Dermatologist’s clinical diagnosis (biopsy 42%) | 81 |
| Guerra et al. (38) | 2016 | Spain | Multicenter | Retrospective | Inception–2015 | Mixed | 7,415 | Psoriasis | NA | 125 |
| Hellström et al. (39) | 2016 | Finland | Monocenter | Prospective | 2013–2014 | Adult | 118 | Psoriasisform lesions | NA | 7 |
| Protic et al. (40) | 2016 | Switzerland | Monocenter | Retrospective | 2010–2013 | NA | 269 | Psoriasis | NA | 23 |
| Vedak et al. (8) | 2016 | USA | Monocenter | Retrospective | 2005–2014 | Adult | 765 | Psoriasisform lesions | Dermatologists | 35 |
| Jeyarajah et al. (9) | 2017 | Ireland | Monocenter | Retrospective | 2000–2015 | NA | 403 | Psoriasis | NA | 8 |
| Peer et al. (10) | 2017 | Australia | Monocenter | Retrospective | 2009–2013 | Adult | 270 | Psoriasisform lesions | Dermatologist and biopsy | 10 |
| Andrade et al. (11) | 2018 | Portugal | Monocenter | Retrospective | 2005–2015 | Mixed | 732 | Psoriasis | NA | 39 |
| Bae et al. (6) | 2018 | Korea | Nationwide | Retrospective | 2007–2016 | Mixed | 5,428 | Psoriasis | NA | 62 |
| Srithar et al. (12) | 2018 | USA | Monocenter | Retrospective | 2010–2015 | Children | 409 | Psoriasis | NA | 33 |
| Weizman et al. (13) | 2018 | Canada | Monocenter | Retrospective | 2004–2016 | Mixed | 676 | Psoriasisform lesions | Dermatologists and biopsy | 72 |
| Courbette et al. (14) | 2019 | France | Monocenter | Retrospective | 2002–2014 | Children | 147 | Psoriasisform lesions | Dermatologists | 20 |
| Cossio et al. (15) | 2020 | Canada | Monocenter | Retrospective | 2013–2016 | Children | 343 | Psoriasis | Dermatologists | 20 |
| Ya et al. (16) | 2020 | USA | Monocenter | Retrospective | 2003–2015 | Adult | 97 | Psoriasis | Dermatologist and biopsy | 97 |

NA, not available; IBD, inflammatory bowel disease.

TNF therapy was 6.0% (95% CI, 5.0–7.0%; I² = 93.9%, n = 29 studies), with 6.9% (95% CI 5.1–8.7%; I² = 88.7%, n = 15 studies) for psoriasiform lesions and 4.6% (95% CI 3.6–5.6%; I² = 93.3%, n = 15 studies) for psoriasis, respectively (Figures 1–3). The results of the jackknife sensitivity analysis suggested that the pooled estimate was robust and not influenced excessively by omitting any single study, ranging from 5.7 to 6.5% (Supplementary Table S2). When tested for publication bias, P was 0.034 for Begg’s test and 0.001 for Egger’s test. Despite the existence of a publication bias, the sensitivity analyses of the trim-and-filled method showed that the result was roughly reliable. We further conducted a sensitivity analysis exclusively including the 23 studies that reported an incidence of de novo psoriasis/psoriasiform lesion, yielding a similar pooled incidence of 5.8% (4.8–6.9%) (6–15, 22, 24, 25, 27, 30–32, 34–38, 40) (Supplementary Figure S2).
In addition, the pooled incidence of psoriasis and/or psoriasiform reaction was separately analyzed according to gender (5.6%, 95% CI: 3.9–7.2% for female, n = 10 studies; 5.6%, 95% CI: 3.9–7.2% for male, n = 10 studies), the types of IBD [4.8%, 95% CI: 3.7–5.9% for Crohn’s disease (CD), n = 14 studies; 3.0%, 95% CI: 1.9–4.1% for ulcerative colitis (UC), n = 12 studies], and anti-TNF agents (5.4%, 95% CI: 4.2–6.5% for infliximab, n = 15 studies; 4.3%, 95% CI: 2.9–5.6% for adalimumab, n = 11 studies; 6.8%, 95% CI: 3.7–9.9% for certolizumab, n = 2 studies) (Supplementary Figures S3–S9).

**Risk Factors for Psoriasis or Psoriasiform Lesions**

Data on clinical associations of psoriasis or psoriasiform lesions following anti-TNF therapy were available from 18 studies (6, 8, 9, 11–16, 25, 26, 30, 32–34, 36, 38, 40). With regard to demographic features, the risk of psoriasis or psoriasiform lesions during anti-TNF therapy was significantly higher in female patients (pooled OR: 1.46, 95% CI: 1.23–1.73, I² = 45.7%, n = 11 studies), with younger age at anti-TNF initiation (pooled OR: 1.03, 95% CI: 1.00–1.05, I² = 65.5%, n = 4 studies), and smoking (pooled OR: 1.97, 95% CI: 1.56–2.48, I² = 52.8%, n = 7 studies) (Figure 4 and Supplementary Figures S10–S12). In the study of Freling et al., IBD patients aged <28 years had a significantly higher risk of developing psoriasiform lesions compared to those >46 years (hazard ratio: 5.21, 95% CI: 8.49).

**Meta-regression and Subgroup Analysis**

Meta-regression analysis was conducted to investigate the source of heterogeneity. Nine covariates, including publication year, setting, study design, region, population, sample size, CD proportion, infliximab proportion, and study quality, were extracted from the 29 included studies. The univariable meta-regression identified three factors potentially related to the heterogeneity, including study design, region, population, and sample size (Table 2). As only 29 studies were included, we further included 3 factors in the multivariable meta-regression, showing region (coefficient -0.244, 95% CI: -0.046 to 0.003, P = 0.029) and population (coefficient -0.023, 95% CI -0.001 to 0.047, P = 0.062) to have significantly contributed to the heterogeneity (Table 2).

We further conducted several subgroup analyses according to region, setting, and study design, sample size, diagnosis method, and study quality (Table 3). These results indicated that the heterogeneity can also be partially explained by the differences in region and population.
2.43–11.16). No significant association was detected regarding white race, obesity/overweight, and family history of psoriasis (Figure 4 and Supplementary Figures S13–S16).

In relation to combinable disease characteristics and treatment regimen, the presence of psoriasis or psoriasiform lesions following anti-TNF exposure was significantly higher in IBD patients receiving adalimumab (OR: 1.48, 95% CI: 1.03–2.13, \(I^2 = 52.8\%\), \(n = 6\) studies) and certolizumab (OR: 2.87, 95% CI: 1.04–7.91, \(I^2 = 62.6\%\), \(n = 2\) studies) than that of infliximab, but not associated with CD (versus UC), longer IBD duration, the presence of extraintestinal manifestations, and concomitant immunosuppressive therapy (Figure 4 and Supplementary Figures S17–S34). Moreover, no significant differences were observed regarding disease behavior and location of CD and the extent of UC, except ileocolonic Crohn’s disease with OR of 1.48 (1.03–2.13, \(I^2 = 30.3\%\), \(n = 5\) studies) (Figure 4 and Supplementary Figures S17–S34). The result of Egger’s and Begg’s tests showed no publication bias for the above-mentioned analyses (Supplementary Table S3).

In addition, other factors were included only in the systematic review rather than in the meta-analysis (Supplementary Table S4) because the assessment was performed only in 1 study. In this systematic review, no significant associations with psoriasis or psoriasiform lesions in IBD patients receiving anti-TNF therapy were observed, except acute psychological stressor (OR: 3.14, 95% CI: 1.10–8.93) (16) and body mass index (OR: 1.12, 95% CI: 1.01–1.24) (30).

**DISCUSSION**

To our knowledge, this is the first systematic review and meta-analysis to comprehensively investigate the incidence of and risk

| Variables                  | Number of studies | Coefficient | P-value | 95% CI          | Adjusted \(R^2\) |
|----------------------------|-------------------|-------------|---------|-----------------|-----------------|
| **Univariate analysis**    |                   |             |         |                 |                 |
| Publication year           | 29                | -0.002      | 0.575   | -0.009, 0.005   | -5.53%          |
| Setting                    | 29                | -0.035      | 0.167   | -0.085, 0.153   | 7.25%           |
| Study design               | 29                | 0.055       | 0.066   | -0.004, 0.111   | -4.33%          |
| Region                     | 29                | -0.023      | 0.073   | -0.049, 0.023   | 10.60%          |
| Population                 | 27                | 0.0289      | 0.025   | -0.004, 0.054   | 26.52%          |
| Sample size                | 29                | -1.05e-05   | 0.444   | -2.06e-05, -3.01e-07 | 20.26%         |
| CD proportion              | 23                | 0.012       | 0.294   | -0.011, 0.051   | -5.44%          |
| IFX proportion             | 21                | 0.037       | 0.618   | -0.116, 0.190   | -7.63%          |
| Psoriasis diagnosis        | 29                | -0.016      | 0.407   | -0.057, 0.024   | -2.69%          |
| Study outcome              | 29                | -0.017      | 0.382   | -0.058, 0.023   | -4.99%          |
| Study quality              | 29                | 0.115       | 0.275   | -0.010, 0.033   | 0.85%           |
| **Multivariate analysis**  |                   |             |         |                 |                 |
| Region                     | 27                | -0.244      | 0.029   | -0.046, 0.003   | 47.63%          |
| Population                 |                   | 0.023       | 0.062   | -0.001, 0.047   |                 |
| Sample size                |                   | -6.66e-06   | 0.234   | -1.52e-05, 3.92e-06 |                 |
factors for psoriasis or psoriasiform lesions secondary to anti-TNF therapy in IBD patients. The overall estimated pooled incidence was 6.0% psoriasis and/or psoriasiform lesions in IBD patients following anti-TNF therapy. Regarding risk factors, female, younger age at anti-TNF therapy initiation, smoking, and adalimumab or certolizumab usage were significantly associated with an increased risk of developing psoriasis or psoriasiform lesions during anti-TNF therapy in IBD patients. These findings have the potential to inform clinical practice for more individualized decisions or precautions and may help us to understand the mechanism of this paradoxical phenomenon.

### TABLE 3 | Subgroup analyses of pooled incidence of psoriasis or psoriasiform lesions associated with anti-tumor necrosis factor therapy in inflammatory bowel disease patients.

| Subgroup | Number of studies | Pooled incidence (95% CI) | $I^2$ |
|----------|------------------|--------------------------|------|
| **Region** |                 |                          |      |
| Europe   | 17              | 7.4% (5.7–9.1%)          | 94.6% |
| North America | 9          | 6.0% (4.0–7.9%)          | 86.2% |
| Asia-Pacific | 3           | 2.2% (5.0–7.0%)          | 77.0% |
| **Setting** |               |                          |      |
| Monocenter | 25             | 6.8% (5.5–8.2%)          | 87.3% |
| Multicenter | 4              | 2.5% (1.5–3.6%)          | 95.0% |
| **Study Design** |           |                          |      |
| Retrospective | 24         | 5.6% (4.6–6.6%)          | 94.3% |
| Prospective | 5              | 13.7% (6.2–21.2%)        | 87.5% |
| **Population** |               |                          |      |
| Children | 6               | 11.01% (7.0–15.1%)       | 81.3% |
| Adult    | 12              | 6.6% (4.8–8.4%)          | 86.9% |
| Mixed    | 9               | 3.7% (2.6–4.7%)          | 93.3% |
| **Sample size** |          |                          |      |
| <500      | 16              | 8.2% (5.9–10.2%)         | 84.2% |
| ≥500      | 13              | 4.9% (3.8–6.0%)          | 95.8% |
| **Diagnosis method** |         |                          |      |
| Gastroenterologist/dermatologist | 15 | 5.6% (4.1–7.2%) | 91.3% |
| Not reported | 14         | 6.4% (5.0–7.7%)         | 94.1% |
| **Newcastle–Ottawa Scale score** | | | |
| <7        | 19              | 4.9% (3.9–5.9%)          | 91.8% |
| ≥7        | 10              | 7.8% (5.5–10.1%)         | 91.0% |

**FIGURE 4** | Forest plots of the odds ratio for the risk of developing psoriasiform lesions and/or psoriasis in inflammatory bowel disease patients receiving anti-tumor necrosis factor therapy.
Anti-TNF agents have assumed the dominant position in the treatment of IBD over the past couple of decades. A large body of evidence confirms the overall good safety profile of the anti-TNF agents. However, with the increased use of these agents, paradoxical inflammation or autoimmune diseases induced by anti-TNF agents have been continuously reported, including cutaneous, articular, ocular, and neurological involvements (41, 42). Of these, paradoxical psoriasis or psoriasiform lesions, being the most prevalent and well-known paradoxical adverse events associated with anti-TNF agents, have been under intense investigation in recent years. At present, paradoxical psoriasis or psoriasiform lesions can no longer be considered rare in clinical routine, with incidence estimates of greater than 20% with the use of anti-TNF agents in some research. For the incidence of psoriasis/psoriasiform rash, our results, overall, were comparable to the results from the 2021 meta-analysis (43). The primary outcome of dermatological reactions in IBD patients receiving anti-TNF therapy from 26 studies was 19.4% (95% CI: 15.2–24.4%, \( I^2 = 95\%\)) in this meta-analysis. In the secondary outcome of psoriasis/psoriasiform rash, there was a pooled incidence of 5.6% (95% CI: 4.2–7.4%, \( I^2 = 95\%\)), with 6.1% (95% CI: 3.4–10.6%, \( I^2 = 96\%\)) for infliximab therapy and 5.9% (95% CI: 2.5–13.5, \( I^2 = 93\%\)) for adalimumab therapy. In addition to this, our work has reported more detailed and more specific information on anti-TNF-associated psoriasis/psoriasiform rash. In the meta-regression and subgroup analyses, we also noticed that the regions and population contributed to the heterogeneity. Taken together, gastroenterologists should be aware of the paradoxical phenomenon, and the current findings could be instrumental in guiding therapeutic decision in clinical routine.

Currently, the molecular mechanisms and pathogenesis of paradoxical psoriasis/psoriasiform rash associated with anti-TNF agents are poorly understood, and multiple factors might be involved, including the genetic predisposition, preexisting autoimmune condition, and increased secretion and imbalance of cytokines and cells (interferon-\( \alpha \), Th1, Th2, Th17 cytokines, etc.). Clinically, the risk factors for developing psoriasis/psoriasiform rash after anti-TNF therapy are under exploration but are inconclusive. The present study, for the first time, has systematically reviewed the literature surrounding the risk factors. The meta-analyses revealed a statistically increased risk of developing psoriasis or psoriasiform lesions during anti-TNF therapy in IBD patients who are female, of a young age at anti-TNF therapy initiation, smoking, and using adalimumab or certolizumab. In the general population, psoriasis can manifest at any age, but with the highest peak between the ages of 20 and 40 years (44). The function of the immune system, and so does autoimmunity, is affected by various factors, including age (45). Overall, age is closely related to the strength of the immune system response, which is expected to decline in senescence (46, 47). From this aspect, the association between advanced age and low risk of psoriasis or psoriasiform lesions secondary to anti-TNF therapy can also be, in part, instinctively understood. In this study, we found that smoking, past and present, is the major risk factor for developing psoriasis during anti-TNF treatment in IBD patients. In fact, the adverse effects of smoking on psoriasis onset have been documented in the general population. The possible pathophysiological mechanisms of the associations included oxidative stress and free radical damage induced by smoking, which could trigger a cascade of systemic inflammation and the subsequent development of psoriasis (48, 49). However, it is still challenging to understand whether or how smoking work together with TNF blockade to orchestrate the psoriasis occurrence. In vitro, cigarette smoke chemical components could activate nuclear factor kappa-B activation and proinflammatory cytokine production, including IL-1\( \beta \) and IL-6 (50). The full blockade of TNF-\( \alpha \) may impair the homeostasis of normal skin and cause an imbalance in cytokines and cells, which may be further exacerbated by the presence of smoking, and finally paradoxical adverse events occur (50). For paradoxical skin inflammation, the IFN-\( \alpha \) pathway was considered to play a key role. However, cigarette smoking was found to decrease the production of IFN-\( \alpha \) and increase the production of IFN-\( \beta \) in vitro (51). Unraveling the synergistic effect between smoking and TNF blockade on the incidence of paradoxical psoriasis can be extremely complex in people with IBD, yet smoking cessation before starting anti-TNF therapy merits consideration in IBD patients from the perspective of decreasing the risk of paradoxical adverse events. In addition, current evidence suggests that paradoxical inflammation during treatment with anti-TNF agents seems to be a drug class effect. In the present study, the significantly higher risk of adalimumab or certolizumab therapy than infliximab therapy was identified, although both of them were associated with an increased risk of paradoxical psoriasis or psoriasiform skin lesions. In fact, potential differences between adalimumab and infliximab in IBD have been reported. In a nationwide cohort study of biologic-naïve adults with UC, the adalimumab-treated patients showed a substantially higher rate of all-cause hospitalization and serious infection requiring hospitalization and a trend toward a higher rate of UC-related hospitalization (52). Besides these, infliximab drug levels were found to be associated with the depth of remission in patients with CD, but no such relationship was detected for adalimumab (53). However, there is no plausible mechanism evidence to explicitly explain the difference among different types of anti-TNF-associated psoriasis or psoriasiform rash. Future clinical and basic science studies are needed to experimentally validate the presented findings.

However, there were several limitations to our study. First, due to the nature of observational design in the original studies, the present study is vulnerable to potential biases (information or selection bias), which cannot allow us to conclude definite causal relationships. Second, the heterogeneity for the pooled incidence among the studies was very high. For this, we performed a series of subgroup analyses, meta-regression, and risk factor exploration. To a large extent, they could explain the source of heterogeneity. Third, various diagnosis criteria of psoriasis or psoriasiform skin lesions were applied in the included studies, mostly by interview or read codes rather than by dermatologists. Establishing a close collaboration between gastroenterologists and dermatologists is necessary to overcome this limitation in the future. Fourth, not all
studies made enough adjustment for potential confounders, and we cannot fully unify the confounders, which can potentially lead to either an overestimation or an underestimation of the associations. Lastly, despite all the potential risk factors evaluated, for some of them, especially for disease activity, cumulative anti-TNF dosages were only included into the systematic review, and further investigations are required to explore their association.

CONCLUSION

In summary, the overall estimated pooled incidence of psoriasis/psoriasiform lesions secondary to anti-TNF therapy was 6% in IBD patients. Female, young age at anti-TNF therapy initiation, smoking, ileocolonic CD, and adalimumab or certolizumab use were associated with a substantially increased risk of developing psoriasis or psoriasiform lesions during anti-TNF therapy. These findings have the potential to inform clinical practice for more individualized decisions or precautions and may help us to understand the mechanism of this paradoxical phenomenon.

REFERENCES

1. Molodecky NA, Soo IS, Rabi DM, Ghali WA, Ferris M, Chernoff G, et al. Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review. *Gastroenterology* (2012) 142(1):A6–5.e42–quiz e30. doi: 10.1053/j.gastro.2011.10.001
2. Ng SC, Shi HY, Hamidi N, Underwood FE, Tang W, Renchimol EI, et al. Worldwide Incidence and Prevalence of Inflammatory Bowel Disease in the 21st Century: A Systematic Review of Population-Based Studies. *Lancet* (2017) 390(10114):2769–78. doi: 10.1016/S0140-6736(17)32448-0
3. D’Haens GR, van Deventer S. 25 Years of Anti-TNF Treatment for Inflammatory Bowel Disease: Lessons From the Past and a Look to the Future. *Gut* (2021) gutjnl-2019-320022. doi: 10.1136/gutjnl-2019-320022
4. Cohen BL, Sachar DB. Update on Anti-Tumor Necrosis Factor Agents and Other New Drugs for Inflammatory Bowel Disease. *BMJ* (2017) 357:j2505. doi: 10.1136/bmj.j2505
5. Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW, et al. Review Article: Managing the Adverse Events Caused by Anti-TNF Therapy in Inflammatory Bowel Disease. *Aliment Pharmacol Ther* (2019) 49(6):664–80. doi: 10.1111/1442-8602.15097
6. Rue JM, Lee HH, Lee BL, Lee KM, Eun SH, Cho ML, et al. Incidence of Psoriasis Disease Secondary to Tumour Necrosis Factor Antagonists in Patients With Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. *Aliment Pharmacol Ther* (2018) 48(2):196–205. doi: 10.1111/apt.14822
7. Mäkelänen T, Wikström A, Heiskanen K, Merras-Salmio L, Mustonen H, Sipponen T, et al. Skin Reactions During Anti-TNFα Therapy for Pediatric Inflammatory Bowel Disease: A 2-Year Prospective Study. *Inflammation Bowel Dis* (2014) 20(8):1309–15. doi: 10.1007/MiB.0000000000000088
8. Vedak P, Kroshinsky D, St John J, Xuan M, Yajnik V, Ananthakrishnan AN, et al. Genetic Basis of TNF-α Antagonist Associated Psoriasis in IBD Patients: A Genotype-Phenotype Analysis. *Aliment Pharmacol Ther* (2016) 43(6):697–704. doi: 10.1111/apt.13542
9. Kiribi Jeyarajah S, Tobin AM, Hussey M, Scaldaferrri F, McNamara D. Anti-Tnf Antibody-Induced Psoriasiform Skin Lesions in Patients With Inflammatory Bowel Disease: An Irish Cohort Study. *QJM* (2017) 110 (6):379–82. doi: 10.1093/qjmed/hcx003
10. Peer FC, Miller A, Pavli P, Subramaniam K. Paradoxical Psoriasiform Reactions of Anti-Tumour Necrosis Factor Therapy in Inflammatory Bowel Disease Patients. *Intern Med J* (2017) 47(12):1445–8. doi: 10.1111/imj.13637
11. Andrade P, Lopes S, Gaspar R, Nunes A, Magina S, Macedo G. Anti-Tumor Necrosis Factor-α-Induced Dermatological Complications in a Large Cohort of Inflammatory Bowel Disease Patients. *Dig Dis Sci* (2018) 63(3):746–54. doi: 10.1007/s10606-018-9421-y
12. Sridhar S, Maltz RM, Boyle B, Kim SC. Dermatological Manifestations in Pediatric Patients With Inflammatory Bowel Disease on Anti-TNF Therapy. *Inflammation Bowel Dis* (2018) 24(9):2086–92. doi: 10.1093/ibd/iyz112
13. Weizman AV, Sharma R, Afzal NM, Xu W, Walsh S, Stempak JM, et al. Structuring and Fistulizing Crohn’s Disease Is Associated With Anti-Tumor Necrosis Factor-Induced Psoriasis in Patients With Inflammatory Bowel Disease. *Dig Dis Sci* (2018) 63(9):2430–8. doi: 10.1007/s10606-018-5096-2
14. Courbette O, Aupiais C, Viala J, Hugot JP, Loubree B, Chatenoud L, et al. Infliximab Paradoxical Psoriasis in a Cohort of Children With Inflammatory Bowel Disease. *J Pediatr Gastroenterol Nutr* (2019) 69(2):189–93. doi: 10.1097/MPG.0000000000002349
15. Cossio ML, Genois A, Jantchou P, Hatami A, Deslandres C, McCuaig C, et al. Skin Manifestations in Pediatric Patients Treated With a TNF-Alpha Inhibitor for Inflammatory Bowel Disease: A Retrospective Study [Formula: See Text]. *J Cutan Med Surg* (2020) 24(4):333–9. doi: 10.1177/1203475420917387
16. Ya J, Hu JZ, Nowacki AS, Khanna U, Zabouni S, Kabbur G, et al. Family History of Psoriasis, Psychological Stressors, and Tobacco Use Are Associated With the Development of Tumor Necrosis Factor-α Inhibitor-Induced Psoriasis: A Case-Control Study. *J Am Acad Dermatol* (2020) 83(6):S599–605. doi: 10.1016/j.jaad.2020.06.081
17. Moher D, Liberati A, Tetzlaff J, PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *BMJ* (2009) 339:b2535. doi: 10.1136/bmj.b2535
18. Stang A. Critical Evaluation of the Newcastle-Ottawa Scale for the Assessment of the Quality of Nonrandomized Studies in Meta-Analyses. *Eur J Epidemiol* (2010) 25(9):603–5. doi: 10.1007/s10654-010-9491-z
19. Xie W, Huang H, Deng X, Gao D, Zhang Z. Modifiable Lifestyle and Environmental Factors Associated With Onset of Psoriatic Arthritis in Patients With Psoriasis: A Systematic Review and Meta-Analysis of Observational Studies. *J Am Acad Dermatol* (2021) 84(3):701–11. doi: 10.1016/j.jaad.2020.08.060
20. Sugiyama D, Nishimura K, Tamaki K, Tsuji G, Nakazawa T, Morinobu A, et al. Impact of Smoking as a Risk Factor for Developing Rheumatoid Arthritis: A Meta-Analysis of Observational Studies. *Ann Rheum Dis* (2010) 69:70–81. doi: 10.1136/ard.2008.096487

DATA AVAILABILITY STATEMENT

The original contributions presented in this study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

AUTHOR CONTRIBUTIONS

ZZ conceptualized the study, participated in its design and coordination, and critically revised the manuscript. WX and SX contributed to data collection, analysis, and interpretation and drafted the manuscript. HH contributed to the process of data collection as a study investigator. All authors contributed to the article and approved the submitted version.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2022.847160/full#supplementary-material
30. Cleynen I, Van Moerkercke W, Billiet T, Vandevelde Laere P, Vande Casteele N, Breyneart C, et al. Characteristics of Skin Lesions Associated With Anti-Tumor Necrosis Factor Therapy in Patients With Inflammatory Bowel Disease: A Cohort Study. *Ann Intern Med* (2016) 164(1):10–22. doi: 10.7326/M15-0729

31. Hellström AE, Barköö M, Kolho KL. Inflammix-Induced Skin Manifestations in Patients With Inflammatory Bowel Disease. *Scand J Gastroenterol* (2016) 51(5):563–71. doi: 10.1080/0033513080305828.

32. Proct M, Schoepfer A, Yawalkar N, Vavricka S, Seibold F. Development of Psoriasis in IBD Patients Under TNF-Antagonist Therapy is Associated Neither With Anti-TNF-Antagonist Antibodies Nor Trough Levels. *Scand J Gastroenterol* (2016) 51(12):1482–8. doi: 10.1007/s00277-016-2185-4.

33. Fiorino G, Danese S, Pariente B, Allez M. Paradoxical Immune-Mediated Inflammation in Inflammatory Bowel Disease Patients Receiving Anti-TNF-α Agents. *Autoimmun Rev* (2014) 13(1):15–9. doi: 10.1016/j.autrev.2013.06.005.

34. Cleynen I, Vermeire S. Paradoxical Inflammation Induced by Anti-TNF Agents in Patients With IBD. *Nat Rev Gastroenterol Hepatol* (2012) 9:496–503. doi: 10.1038/nrgastro.2012.125.

35. Nigam GB, Bhandare AP, Antoniou GA, Limdi JK. Systematic Review and Meta-Analysis of Dermatological Reactions in Patients With Inflammatory Bowel Disease Treated With Anti-Tumour Necrosis Factor Therapy. *Eur J Gastroenterol Hepatol* (2021) 33(3):346–57. doi: 10.1097/MEG.00000000000001917.

36. Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics Targeting the IL-23 and IL-17 Pathway in Psoriasis. *Lancet* (2021) 397(10275):754–66. doi: 10.1016/S0140-6736(21)00184-7.

37. Nigam GB, Singh H, Mukhopadhyay A. Gut Bacterial Peptides With Autointerference Potential as Environmental Trigger for Late Onset Complex Diseases: In-Silico Study. *PloS One* (2017) 12(7):e0180518. doi: 10.1371/journal.pone.0180518.

38. Xu D, Wang B, Chen L, Zhang H, Wang X, Chen J. The Incidence and Mortality Trends of Bone Lymphoma in the United States: An Analysis of the Surveillance, Epidemiology, and End Results Database. *J Bone Oncol* (2020) 24:100306. doi: 10.1016/j.jbono.2020.100306.

39. Martinez-Jimenez CP, Eling N, Chen HC, Vallejos CA, Kolodziejczyk AA, Connor F, et al. Aging Increases Cell-to-Cell Transcriptional Variability Upon Immunostimulation. *Science* (2018) 359(6352):1423–6. doi: 10.1126/science.aab4115.

40. Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and Smoking: A Systematic Review and Meta-Analysis. *Br J Dermatol* (2014) 170(2):304–11. doi: 10.1111/bjd.12670.

41. Yanbaeva DG, Dennter MA, Creutzberg EC, Wesseling G, Wouters EF. Systemic Effects of Smoking. *Chest* (2007) 131(5):1557–66. doi: 10.1378/ chest.06.2179.

42. Nii T, Kuzuya K, Kabata D, Matsu T, Murata A, Ohya T, et al. Crosstalk Between Tumor Necrosis Factor-Alpha Signaling and Aryl Hydrocarbon Receptor Signaling in Nuclear Factor-κB Activation: A Possible Molecular Mechanism Underlying the Reduced Efficacy of TNF-Inhibitors in Rheumatoid Arthritis by Smoking. *J Autoimmun* (2019) 98:95–102. doi: 10.1016/j.jaut.2018.12.004.

43. Liebhart I, Cembrytnska-Nowak M, Kulczak A, Siemiencik I. Diverse Production of Interferons Alpha, Beta, and Gamma by Airway Leucocytes of Asthmatics With Regard to Cigarette Smoking and Corticosteroid Treatment. *J Interferon Cytokine Res* (2007) 27(6):463–70. doi: 10.1089/ jir.2007.0102.

44. Singh S, Andersen NN, Andressen M, Loftus EV Jr, Jess T. Comparison of Infliximab and Adalimumab in Biologic-Naive Patients With Ulcerative Colitis: A Nationwide Danish Cohort Study. *Clin Gastroenterol Hepatol* (2017) 15(8):1218–1225.e7. doi: 10.1016/j.cgh.2016.11.024.

45. Ward MG, Warner B, Unsworth N, Chua SW, Brownclaire C. Inflamximab and Adalimumab Drug Levels in Crohn’s Disease: Contrasting Associations.
With Disease Activity and Influencing Factors. *Aliment Pharmacol Ther* (2017) 46(2):150–61. doi: 10.1111/apt.14124

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2022 Xie, Xiao, Huang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.